The research collaboration between AstraZeneca and Insitro, announced on October 15, 2026, targets metabolic dysfunction-associated steatohepatitis, a fatty liver condition, and cardiomyopathies, which are diseases affecting the heart muscle

From the articleAstraZeneca and Insitro Ink $1.86 Billion AI Drug Discovery DealAlso in AstraZeneca Strikes Up to $1.5 Billion AI Drug Discovery Deal With Insitro